Canadian Pharmaceutical Retail Groups Place Test Market Orders for Product Designed to Detect Over 60 Date-Rape Drugs in 30 Seconds. HUNTINGTON BEACH, Calif., (GVIPT), March 1 /PRNewswire-FirstCall/ -- WayPoint Biomedical, Inc. (OTC:WYPH) receives test market orders for Drink Detective(TM) from two key Canadian Retail Pharmacy groups, United Pharmacies in Saskatchewan and Procurity Pharmacy Service Chain Stores in Manitoba. WayPoint Director of Sales and Marketing, Phill Richer, remarks, "With over 260 combined stores, the acceptance to test market the Drink Detective date-rape drug detection kit by these two pharmacy chains marks WayPoint's first success entering the OTC retail field in Canada." Sales and Marketing Director for recently retained internet marketing firm, Global VIP Traffic, by WayPoint states, "We are eager to become a part of this company's marketing efforts. They are consistently offering high quality products that focus on not only providing solutions, but a higher level of education as well." About WayPoint Biomedical WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (OTC:WYPH), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical, visit http://www.waypointbiomedical.com/, http://www.drinkdetectiveusa.com/. Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law. DATASOURCE: WayPoint Biomedical, Inc. CONTACT: Dennis Shepherd, +1-714-848-3200, , or Investors, David Kugelman, +1-866-692-6847, both of WayPoint Biomedical, Inc. Web site: http://www.drinkdetectiveusa.com/ Web site: http://www.waypointbiomedical.com/

Copyright